IDEAYA Biosciences, Inc.

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website: https://ir.ideayabio.com/.

Current securities

1. 10-Q filingAug 4, 2026
2. Results of Operations and Financial ConditionAug 4, 2026
3. 144 filingJul 7, 2026
4. Submission of Matters to a Vote of Security Holders · Other EventsJun 23, 2026
5. 4 filingJun 18, 2026